Elzovantinib, also known as TPX-0022 and CSF1R-IN-2, is an orally bioavailable CSF1R inhibitor with a novel three-dimensional macrocyclic structure that inhibits the MET, CSF1R (colony stimulating factor 1 receptor) and SRC kinases. Targeting CSF1R leads to the modulation of tumor-associated macrophages (TAMs), a type of immune cell that suppresses the T-cell mediated anti-tumor immune response. Inhibition of CSF1R with TPX-0022 is a promising therapeutic strategy as a single agent or in combination with standard of care chemotherapy and immunotherapy in various solid tumors.
MedKoo Cat#: 408118
Name: Elzovantinib
CAS#: 2271119-26-5
Chemical Formula: C20H20FN7O2
Exact Mass: 409.1663
Molecular Weight: 409.43
Elemental Analysis: C, 58.67; H, 4.92; F, 4.64; N, 23.95; O, 7.82
The following data is based on the product molecular weight 409.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
